Guselkumab Provides Relief For Patients Who Suffer With Psoriasis Overview A 52-week postmarketing surveillance study was launched to assess the safety and effectiveness of guselkumab, a human monoclonal antibody targeting the interleukin-23 subunit p19, in Japanese patients diagnosed with psoriasis vulgaris, psoriatic arthritis, generalized pustular psoriasis, and erythrodermic psoriasis in real-world clinical
Tag: guselkumab
